Anna Pavlick is an Oncology physician. ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1305 York Ave Fl 12
New York, NY 100215663
Telephone
646-962-6444Provider last certified this registry record 2 May 2023.
Clinical trials
- Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Sponsor: Weill Medical College of Cornell University
- Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Sponsor: Melissa Burgess, MD
- RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20251 payment
- ARRAY BIOPHARMA INCProgram year20251 payment
- BioNTech SEProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
96.6%PD-1 inhibitor83.5%Nivolumab100%Part B, office-administered≥17 patientsCTLA-4-directed Blocking Antibody13%Ipilimumab100%Part B, office-administered≥11 patients+ 2 more classes in this area
Sensory organs
2.9%Corticosteroid2.9%Dexamethasone sodium phosphate100%Part B, office-administered≥19 patientsMetabolism & gastrointestinal
0.2%Corticosteroid0.1%Prednisone100%Part D≥19 patientsH2 blocker0.1%Famotidine100%Part D≥18 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1998–2019 per NIH RePORTER. The latest:
- Clinical Protocol and Data Management
New York University School of Medicine
FY2019$541,684P30CA016087 - NSABP P-2: STUDY OF TAMOXIFEN AND RALOXIFENE( STAR) TO PREVENT BREAST CANCER
New York University School of Medicine
FY2005$955M01RR000096 - Thalidomide and Dacarbazine for Metastatic Melanoma
New York University School of Medicine
FY2004$3,302M01RR000096
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”